<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10980961</article-id><article-id pub-id-type="pmcid-ver">PMC10980961.1</article-id><article-id pub-id-type="pmcaid">10980961</article-id><article-id pub-id-type="pmcaiid">10980961</article-id><article-id pub-id-type="pmid">38551564</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2024.3387</article-id><article-id pub-id-type="publisher-id">zoi240151</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge</article-title><alt-title alt-title-type="headline">Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge</alt-title><alt-title alt-title-type="running-head">Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bernstein</surname><given-names initials="EY">Eden Y.</given-names></name><degrees>MD</degrees><xref rid="zoi240151aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi240151aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baggett</surname><given-names initials="TP">Travis P.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="zoi240151aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi240151aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi240151aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Trivedi</surname><given-names initials="S">Shrunjal</given-names></name><degrees>MPH</degrees><xref rid="zoi240151aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herzig</surname><given-names initials="SJ">Shoshana J.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="zoi240151aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi240151aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anderson</surname><given-names initials="TS">Timothy S.</given-names></name><degrees>MD</degrees><degrees>MAS</degrees><xref rid="zoi240151aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="zoi240151aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="zoi240151aff1"><label>1</label>Division of General Internal Medicine, Massachusetts General Hospital, Boston,</aff><aff id="zoi240151aff2"><label>2</label>Harvard Medical School, Boston, Massachusetts</aff><aff id="zoi240151aff3"><label>3</label>Institute for Research, Quality, and Policy in Homeless Health Care, Boston Health Care for the Homeless Program, Boston, Massachusetts</aff><aff id="zoi240151aff4"><label>4</label>Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts</aff><aff id="zoi240151aff5"><label>5</label>Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> January 10, 2024.</p><p content-type="published-online"><bold>Published:</bold> March 29, 2024. doi:<uri content-type="doi">10.1001/jamanetworkopen.2024.3387</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2024 Bernstein EY et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi240151cor1"><bold>Corresponding Author:</bold> Eden Y. Bernstein, MD, Division of General Internal Medicine, Massachusetts General Hospital, 100 Cambridge St, 16th Floor, Boston, MA 02114 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eybernstein@mgh.harvard.edu">eybernstein@mgh.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Anderson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Bernstein, Baggett, Anderson.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Bernstein, Trivedi, Herzig, Anderson.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Bernstein.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Baggett, Trivedi, Herzig, Anderson.</p><p><italic toggle="yes">Statistical analysis:</italic> Bernstein, Trivedi, Anderson.</p><p><italic toggle="yes">Obtained funding:</italic> Herzig, Anderson.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Anderson.</p><p><italic toggle="yes">Supervision:</italic> Baggett, Herzig, Anderson.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Bernstein reported receiving personal fees from Alosa Health outside the submitted work. Dr Anderson reported receiving grants from the American Heart Association, American College of Cardiology, US Deprescribing Research Network, and Boston Claude D. Pepper Older Americans Independence Center outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> Dr Bernstein received funding support from an Institutional National Research Service Award T32HP32715 and from the Massachusetts General Hospital Division of General Internal Medicine. Dr Herzig was supported by grant R01HS026215 from the Agency for Healthcare Research and Quality. Dr Anderson was supported by grant K76AG074878 from the National Institute on Aging. Dr Baggett was supported by the Massachusetts General Hospital Research Scholars Program.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The research reported in this publication was supported by the Agency for Healthcare Research and Quality and National Institute on Aging of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality or the National Institutes of Health.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-03-29T10:00"><day>29</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><volume>7</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">458898</issue-id><elocation-id>e243387</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>31</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-31 00:25:15.183"><day>31</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 Bernstein EY et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e243387.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e243387.pdf">jamanetwopen-e243387.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.3387"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Netw Open" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38551570"><article-title>Sobering Perspectives on the Treatment of Alcohol Use Disorder.</article-title><volume>7</volume><issue>3</issue><date><day>4</day><month>3</month><year>2024</year></date><fpage>e243340</fpage><lpage>e243340</lpage><source>JAMA Netw Open</source><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.3340</pub-id><pub-id pub-id-type="pmid">38551570</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study investigates the association of medications for alcohol use disorder initiated at hospital discharge with return to hospital or death after alcohol-related hospitalizations.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi240151-1"><title>Question</title><p>Is the initiation of medications for alcohol use disorder at hospital discharge associated with 30-day clinical outcomes among Medicare Part D beneficiaries?</p></sec><sec id="ab-zoi240151-2"><title>Findings</title><p>In this cohort study of 9834 alcohol-related hospitalizations, discharge initiation of medications for alcohol use disorder was associated with an absolute risk reduction of 18% in the composite outcome of return to hospital or death within 30 days compared with no initiation.</p></sec><sec id="ab-zoi240151-3"><title>Meaning</title><p>These findings support efforts to increase initiation of medications for alcohol use disorder at hospital discharge.</p></sec></abstract><abstract><sec id="ab-zoi240151-4"><title>Importance</title><p>US Food and Drug Administration&#8211;approved medications for alcohol use disorder (MAUD) are significantly underused. Hospitalizations may provide an unmet opportunity to initiate MAUD, but few studies have examined clinical outcomes of patients who initiate these medications at hospital discharge.</p></sec><sec id="ab-zoi240151-5"><title>Objective</title><p>To investigate the association between discharge MAUD initiation and 30-day posthospitalization outcomes.</p></sec><sec id="ab-zoi240151-6"><title>Design, Setting, and Participants</title><p>This cohort study was conducted among patients with Medicare Part D who had alcohol-related hospitalizations in 2016. Data were analyzed from October 2022 to December 2023.</p></sec><sec id="ab-zoi240151-7"><title>Exposures</title><p>Discharge MAUD initiation was defined as oral naltrexone, acamprosate, or disulfiram pharmacy fills within 2 days of discharge.</p></sec><sec id="ab-zoi240151-8"><title>Main outcomes</title><p>The primary outcome was a composite of all-cause mortality or return to hospital (emergency department visits and hospital readmissions) within 30 days of discharge. Secondary outcomes included these components separately, return to hospital for alcohol-related diagnoses, and primary care or mental health follow-up within 30 days of discharge. Propensity score 3:1 matching and modified Poisson regressions were used to compare outcomes between patients who received and did not receive discharge MAUD.</p></sec><sec id="ab-zoi240151-9"><title>Results</title><p>There were 6794 unique individuals representing 9834 alcohol-related hospitalizations (median [IQR] age, 54 [46-62] years; 3205 hospitalizations among females [32.6%]; 1754 hospitalizations among Black [17.8%], 712 hospitalizations among Hispanic [7.2%], and 7060 hospitalizations among White [71.8%] patients). Of these, 192 hospitalizations (2.0%) involved discharge MAUD initiation. After propensity matching, discharge MAUD initiation was associated with a 42% decreased incidence of the primary outcome (incident rate ratio, 0.58 [95% CI, 0.45 to 0.76]; absolute risk difference, &#8722;0.18 [95% CI, &#8722;0.26 to &#8722;0.11]). These findings were consistent among secondary outcomes (eg, incident rate ratio for all-cause return to hospital, 0.56 [95% CI, 0.43 to 0.73]) except for mortality, which was rare in both groups (incident rate ratio, 3.00 [95% CI, 0.42 to 21.22]). Discharge MAUD initiation was associated with a 51% decreased incidence of alcohol-related return to hospital (incident rate ratio, 0.49 [95% CI, 0.34 to 0.71]; absolute risk difference, &#8722;0.15 [95% CI, &#8722;0.22 to &#8722;0.09]).</p></sec><sec id="ab-zoi240151-10"><title>Conclusion and relevance</title><p>In this cohort study, discharge initiation of MAUD after alcohol-related hospitalization was associated with a large absolute reduction in return to hospital within 30 days. These findings support efforts to increase uptake of MAUD initiation at hospital discharge.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI240151"><title>Introduction</title><p>In the US, alcohol use disorder (AUD) affects 29 million adults and imposes an annual economic burden of more than $250 billion.<sup><xref rid="zoi240151r1" ref-type="bibr">1</xref>,<xref rid="zoi240151r2" ref-type="bibr">2</xref></sup> Excessive alcohol use is also the fourth leading cause of preventable mortality in the US, contributing to more than 140&#8201;000 annual deaths.<sup><xref rid="zoi240151r1" ref-type="bibr">1</xref></sup> Guideline-recommended treatment for AUD consists of behavioral interventions and medications for AUD (MAUD),<sup><xref rid="zoi240151r3" ref-type="bibr">3</xref></sup> including naltrexone, acamprosate, and disulfiram, which are approved by the Food and Drug Administration (FDA).<sup><xref rid="zoi240151r4" ref-type="bibr">4</xref></sup> Despite guideline recommendations, fewer than 2% of US adults with AUD received MAUD in 2019.<sup><xref rid="zoi240151r3" ref-type="bibr">3</xref>,<xref rid="zoi240151r5" ref-type="bibr">5</xref></sup></p><p>Evidence supporting MAUD efficacy includes randomized clinical trials predominantly based in the outpatient setting with an end point of reduction in drinking.<sup><xref rid="zoi240151r6" ref-type="bibr">6</xref>,<xref rid="zoi240151r7" ref-type="bibr">7</xref></sup> Oral naltrexone has been shown to reduce return to any drinking and heavy drinking, and acamprosate reduced return to any drinking among patients who achieved abstinence.<sup><xref rid="zoi240151r6" ref-type="bibr">6</xref>,<xref rid="zoi240151r7" ref-type="bibr">7</xref></sup> Use of naltrexone has also been associated with reduced hospitalizations using observational data.<sup><xref rid="zoi240151r8" ref-type="bibr">8</xref></sup> Evidence supporting the efficacy of disulfiram is more limited, although it is recommended to use under specific circumstances, including patient preference or intolerance to naltrexone or acamprosate.<sup><xref rid="zoi240151r3" ref-type="bibr">3</xref></sup></p><p>Hospitalizations may serve as important touch points for AUD treatment engagement.<sup><xref rid="zoi240151r9" ref-type="bibr">9</xref></sup> Prescribing MAUD or referring patients to addiction treatment at discharge is a Joint Commission quality measure.<sup><xref rid="zoi240151r10" ref-type="bibr">10</xref></sup> However, postdischarge MAUD initiation among patients enrolled in Medicare rarely occurs.<sup><xref rid="zoi240151r11" ref-type="bibr">11</xref></sup> Reasons for underuse of MAUD are multifactorial and are in part associated with limited knowledge of effectiveness.<sup><xref rid="zoi240151r12" ref-type="bibr">12</xref>,<xref rid="zoi240151r13" ref-type="bibr">13</xref></sup> To our knowledge, few studies have examined outcomes associated with MAUD initiation at hospital discharge.<sup><xref rid="zoi240151r14" ref-type="bibr">14</xref></sup> There were mixed results in 2 single-center, noncontrolled studies that examined preintervention vs postintervention 30-day readmission rates after implementation of interventions that increased naltrexone prescribing.<sup><xref rid="zoi240151r15" ref-type="bibr">15</xref>,<xref rid="zoi240151r16" ref-type="bibr">16</xref></sup> Therefore, we applied a target trial emulation framework<sup><xref rid="zoi240151r17" ref-type="bibr">17</xref></sup> to investigate the association between discharge MAUD initiation and 30-day posthospitalization outcomes among Medicare beneficiaries hospitalized for alcohol-related conditions.</p></sec><sec id="H1-2-ZOI240151"><title>Methods</title><p>We conducted a retrospective cohort study designed to emulate a randomized clinical trial of hospitalized patients with AUD (eTable 1 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>). We used the 20% national sample of Centers for Medicare &amp; Medicaid Services (CMS) administrative and pharmacy claims from 2015 to 2017. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline. This project was approved by the CMS privacy board and the Beth Israel Deaconess Medical Center Institutional Review Board, which also waived informed consent due to the use of deidentified claims data.</p><sec id="H2-1-ZOI240151"><title>Population</title><p>The study sample included all persons who were continuously enrolled in Medicare Parts A, B, and D in the 12 months prior and 12 months after cohort entry or until death within 12 months after cohort entry. Beneficiaries enrolled in a Medicare Advantage plan at any point during the year were excluded due to unavailable administrative claims.</p><p>The cohort consisted of patients with acute care AUD hospitalizations in 2016 who were discharged to the community. AUD hospitalizations included those with a primary discharge diagnosis of AUD or a secondary diagnosis of AUD and a primary mental health discharge diagnosis. Given that the unit of analysis was unique hospitalization, patients could contribute multiple observations to the cohort. Mental health diagnoses were identified using the Healthcare Cost and Utilization Project Clinical Classification Software.<sup><xref rid="zoi240151r18" ref-type="bibr">18</xref></sup> AUD was defined using <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems, Tenth Revision </italic>(<italic toggle="yes">ICD-10</italic>) discharge diagnosis codes for alcohol abuse, dependence, and use (F10.1, F10.2, and F10.9), excluding &#8220;in remission&#8221; specifiers (F10.11, F10.21, and F10.91).<sup><xref rid="zoi240151r19" ref-type="bibr">19</xref></sup> To identify individuals newly receiving MAUD, patients with a pharmacy claim for naltrexone, acamprosate, or disulfiram within 90 days prior to hospitalization were excluded. Patients with liver disease and kidney failure (contraindications for naltrexone and acamprosate, respectively) were excluded. Liver disease and kidney failure were defined by discharge Elixhauser <italic toggle="yes">ICD-10</italic> codes and inpatient hemodialysis claims.<sup><xref rid="zoi240151r20" ref-type="bibr">20</xref></sup></p></sec><sec id="H2-2-ZOI240151"><title>Outcomes</title><p>The primary outcome was a composite of all-cause mortality or return to hospital (including emergency department [ED] visits and readmissions [hospital or observation admissions]) within 30 days of discharge. Secondarily, we examined individual components of the composite outcome separately. We also investigated alcohol-related return to hospital; this was defined using primary or secondary <italic toggle="yes">ICD-10</italic> codes for acute alcohol-attributable diseases, which included previously mentioned AUD codes and other medical diagnoses related to alcohol (eTable 2 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi240151r21" ref-type="bibr">21</xref></sup> Finally, we examined outpatient primary care or mental health follow-up because these events are necessary for posthospitalization care transitions and ongoing AUD treatment (eTable 3 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-3-ZOI240151"><title>Exposure</title><p>The exposure of interest was discharge MAUD initiation, defined as a pharmacy claim for oral naltrexone, acamprosate, or disulfiram fills between the day before discharge and 2 days after discharge. Patients without discharge MAUD initiation were categorized as such regardless of subsequent MAUD fills. To avoid immortal time bias, we excluded patients who died or were readmitted prior to time zero, which was 2 days after hospital discharge.<sup><xref rid="zoi240151r22" ref-type="bibr">22</xref></sup></p></sec><sec id="H2-4-ZOI240151"><title>Covariates</title><p>Covariates included sociodemographics, clinical factors, and hospitalization factors. Sociodemographic variables included age, sex, race and ethnicity, and census region. Race and ethnicity were self-reported and imputed using the Research Triangle Institute race code<sup><xref rid="zoi240151r23" ref-type="bibr">23</xref></sup> and were categorized as Hispanic of any race, non-Hispanic Black, non-Hispanic White, and other (including Asian, North American Native, and unknown, grouped due to small sample size). Race and ethnicity were included due to known disparities in AUD treatment. Medicaid dual eligibility was used to approximate lower income. County-level socioeconomic variables measured using the social deprivation index were included to account for socioeconomic disadvantage.<sup><xref rid="zoi240151r24" ref-type="bibr">24</xref></sup> We also included reason for entitlement to distinguish Medicare eligibility due to age vs disability. Patients with entitlement due to end-stage kidney disease (53 patients) were excluded because none received MAUD and thus a propensity score could not be estimated.</p><p>Clinical factors included medical and psychiatric comorbidities obtained from CMS Chronic Conditions Data Warehouse algorithms.<sup><xref rid="zoi240151r25" ref-type="bibr">25</xref></sup> Remote prior use of MAUD was defined using pharmacy claims for MAUD filled between 90 and 365 days prior to admission. We also included variables for health care use within the past year, including hospitalizations and ED visits. Alcohol withdrawal documented in any care setting (<italic toggle="yes">ICD-10</italic> codes F10.13, F10.23, and F10.93) and presence of alcohol-related comorbidities within the past year may correlate with more severe disease and so were also included (eTable 2 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>). Behavioral treatment in the past 30 days and past year were identified using procedure codes for psychosocial and behavioral therapy as defined in prior literature.<sup><xref rid="zoi240151r26" ref-type="bibr">26</xref></sup></p><p>Hospitalization factors included an indicator variable for a primary discharge diagnosis of AUD, mood disorder, or other mental health diagnosis defined using Clinical Classification Software.<sup><xref rid="zoi240151r18" ref-type="bibr">18</xref></sup> The Elixhauser Comorbidity Index was used to measure comorbidity burden.<sup><xref rid="zoi240151r20" ref-type="bibr">20</xref></sup> A 3-level categorical variable for degree of psychiatric involvement in the hospitalization was created, comprising levels of psychiatric hospital, inpatient care by psychiatry or addiction medicine at a general hospital, or no psychiatry or addiction medicine involvement (eTable 4 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement</xref>). Other hospitalization variables included self-directed discharge (defined by disposition of discharge against medical advice), length of hospital stay, and discharge month.</p></sec><sec id="H2-5-ZOI240151"><title>Statistical Analysis</title><p>We applied propensity score matching to account for confounding by indication in associations between discharge MAUD initiation and posthospitalization outcomes. In our primary analysis, we estimated the propensity for receiving discharge MAUD initiation using aforementioned covariates in a logistic regression and used these propensity scores to perform a nearest-neighbor 3:1 match with replacement (caliper width, 0.2 of the SD of the logit of the propensity score).<sup><xref rid="zoi240151r27" ref-type="bibr">27</xref>,<xref rid="zoi240151r28" ref-type="bibr">28</xref></sup> Covariate balance between groups was assessed using standard mean differences and propensity score distributions. We evaluated the association between discharge MAUD initiation and each outcome using modified Poisson regressions (Poisson regressions with robust variance) to estimate incident rate ratios (IRRs) and absolute risk differences (ARDs).<sup><xref rid="zoi240151r29" ref-type="bibr">29</xref></sup></p><p>Unadjusted outcomes were reported using modified Poisson regressions clustered by individual patients to account for repeated hospitalizations. We performed several sensitivity analyses to assess the robustness of our findings. First, because outcomes after 1 hospitalization may be affected by prior hospitalizations, we restricted our cohort to a single randomly selected hospitalization per patient and applied the same analytic approach. Second, because matching estimates treatment-associated outcomes among only the subset of patients who were matched, we applied overlap weighting, a method that weighs all observations in the cohort based on their probability of belonging to the opposite treatment group.<sup><xref rid="zoi240151r30" ref-type="bibr">30</xref></sup> We used overlap-weighted modified Poisson models with robust standard errors to account for clustering of repeated hospitalizations. Third, to increase comparability between treatment groups, we repeated the primary analysis using only the subgroup of patients with a primary AUD discharge diagnosis. Fourth, because patients who fill discharge medications may be more engaged in treatment compared with those who do not fill any medications, we restricted our cohort to patients who had at least 1 pharmacy fill for any medication within 2 days of discharge.</p><p>Finally, an E-value for the point estimate and CI was calculated to describe the minimum strength of association between treatment and outcome an unmeasured confounder would require in order to shift the effect size or CI to the null.<sup><xref rid="zoi240151r31" ref-type="bibr">31</xref></sup> Results were considered statistically significant when 95% CIs did not cross 1. All analyses were performed using Stata statistical software version 16.1 (StataCorp). Analysis was conducted in October 2022 to December 2023.</p></sec></sec><sec id="H1-3-ZOI240151"><title>Results</title><p>After excluding 2 hospitalizations that had an unspecified county code, we identified 9834 alcohol-related hospitalizations (median [IQR] age, 54 [46-62] years; 3205 hospitalizations among females [32.6%]; 1754 hospitalizations among Black [17.8%], 712 hospitalizations among Hispanic [7.2%], and 7060 hospitalizations among White [71.8%] individuals) representing 6794 unique individuals. Overall, 192 hospitalizations (2.0%) involved discharge MAUD initiation, including 112 hospitalizations (58.3%) with naltrexone, 53 hospitalizations (27.6%) with acamprosate, and 32 hospitalizations (16.7%) with disulfiram initiations; 9642 hospitalizations (98.0%) did not involve discharge MAUD. Prior to matching, a lower proportion of patients who received discharge MAUD initiation had prior psychosis (49 patients [25.5%] vs 3834 patients [39.8%]) and tobacco use disorder (98 patients [51.0%] vs 6402 patients [66.4%]) and a greater proportion had prior remote MAUD use (16 patients [8.3%] vs 171 patients [1.8%]) (<xref rid="zoi240151t1" ref-type="table">Table 1</xref>). They were also more likely to have received care at psychiatric hospitals (85 patients [44.3%] vs 3225 patients [33.5%]) and by psychiatry or addiction medicine when hospitalized at general hospitals (65 patients [33.9%] vs 2477 patients [25.7%]). After matching, there was small residual imbalance in discharge month, but all other covariates were balanced, with standardized mean differences less than 0.1 (eFigure 1 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><table-wrap position="float" id="zoi240151t1" orientation="portrait"><label>Table 1. </label><caption><title>Cohort Characteristics Before and After 3:1 Propensity Matching</title></caption><table frame="hsides" rules="groups"><col width="30.24%" span="1"/><col width="14.57%" span="1"/><col width="14.63%" span="1"/><col width="6.24%" span="1"/><col width="14.57%" span="1"/><col width="14.6%" span="1"/><col width="5.15%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Hospitalizations before matching, No. (%) (N&#8201;=&#8201;9834)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">SMD</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Hospitalizations after matching, No. (%) (N&#8201;=&#8201;768)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">SMD</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discharge MAUD (n&#8201;=&#8201;192)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No discharge MAUD (n&#8201;=&#8201;9642)</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discharge MAUD (n&#8201;=&#8201;192)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No discharge MAUD (n&#8201;=&#8201;576)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Demographic</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age, mean (SD), y</td><td valign="top" align="left" rowspan="1" colspan="1">53.5 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">53.8 (12.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">53.5 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">53.4 (13.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">79 (41.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3126 (32.4)</td><td rowspan="2" valign="middle" align="left" colspan="1">0.18</td><td valign="top" align="left" rowspan="1" colspan="1">79 (41.1)</td><td valign="top" align="left" rowspan="1" colspan="1">225 (39.1)</td><td rowspan="2" valign="middle" align="left" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">113 (58.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6516 (67.6)</td><td valign="top" colspan="1" align="left" rowspan="1">113 (58.9)</td><td valign="top" align="left" rowspan="1" colspan="1">351 (60.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Race and ethnicity<xref rid="zoi240151t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td rowspan="4" valign="middle" align="left" colspan="1">0.20</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td rowspan="4" valign="middle" align="left" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" colspan="1" align="left" rowspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" colspan="1" align="left" rowspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi240151t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" colspan="1" align="left" rowspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Social deprivation index, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">47.2 (26.1)</td><td valign="top" align="left" rowspan="1" colspan="1">50.2 (28.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td><td valign="top" align="left" rowspan="1" colspan="1">47.2 (26.1)</td><td valign="top" align="left" rowspan="1" colspan="1">48.4 (27.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Region</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Northeast</td><td valign="top" align="left" rowspan="1" colspan="1">59 (30.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2826 (29.3)</td><td rowspan="4" valign="middle" align="left" colspan="1">0.07</td><td valign="top" align="left" rowspan="1" colspan="1">59 (30.7)</td><td valign="top" align="left" rowspan="1" colspan="1">173 (30.0)</td><td rowspan="4" valign="middle" align="left" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Midwest</td><td valign="top" align="left" rowspan="1" colspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2295 (23.8)</td><td valign="top" colspan="1" align="left" rowspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">121 (21.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> South</td><td valign="top" align="left" rowspan="1" colspan="1">69 (35.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3265 (33.9)</td><td valign="top" colspan="1" align="left" rowspan="1">69 (35.9)</td><td valign="top" align="left" rowspan="1" colspan="1">211 (36.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> West</td><td valign="top" align="left" rowspan="1" colspan="1">22 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1256 (13.0)</td><td valign="top" colspan="1" align="left" rowspan="1">22 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">71 (12.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicaid dual eligibility</td><td valign="top" align="left" rowspan="1" colspan="1">135 (70.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7361 (76.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.14</td><td valign="top" align="left" rowspan="1" colspan="1">135 (70.3)</td><td valign="top" align="left" rowspan="1" colspan="1">402 (69.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Reason for entitlement</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age</td><td valign="top" align="left" rowspan="1" colspan="1">31 (16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1458 (15.1)</td><td rowspan="2" valign="middle" align="left" colspan="1">0.03</td><td valign="top" align="left" rowspan="1" colspan="1">31 (16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">93 (16.1)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;0.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Disability</td><td valign="top" align="left" rowspan="1" colspan="1">161 (83.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8186 (84.9)</td><td valign="top" colspan="1" align="left" rowspan="1">161 (83.9)</td><td valign="top" align="left" rowspan="1" colspan="1">483 (83.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Clinical</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiety disorder</td><td valign="top" align="left" rowspan="1" colspan="1">117 (60.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6236 (64.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td><td valign="top" align="left" rowspan="1" colspan="1">117 (60.9)</td><td valign="top" align="left" rowspan="1" colspan="1">354 (61.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Depression</td><td valign="top" align="left" rowspan="1" colspan="1">180 (93.8)</td><td valign="top" align="left" rowspan="1" colspan="1">8508 (88.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.19</td><td valign="top" align="left" rowspan="1" colspan="1">180 (93.8)</td><td valign="top" align="left" rowspan="1" colspan="1">548 (95.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Posttraumatic stress disorder</td><td valign="top" align="left" rowspan="1" colspan="1">36 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1818 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.01</td><td valign="top" align="left" rowspan="1" colspan="1">36 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">100 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychosis</td><td valign="top" align="left" rowspan="1" colspan="1">49 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3834 (39.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td><td valign="top" align="left" rowspan="1" colspan="1">49 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (24.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bipolar disorder</td><td valign="top" align="left" rowspan="1" colspan="1">79 (41.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4718 (48.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.16</td><td valign="top" align="left" rowspan="1" colspan="1">79 (41.1)</td><td valign="top" align="left" rowspan="1" colspan="1">242 (42.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tobacco use disorder</td><td valign="top" align="left" rowspan="1" colspan="1">98 (51.0)</td><td valign="top" align="left" rowspan="1" colspan="1">6402 (66.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td><td valign="top" align="left" rowspan="1" colspan="1">98 (51.0)</td><td valign="top" align="left" rowspan="1" colspan="1">294 (51.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Opioid use disorder</td><td valign="top" align="left" rowspan="1" colspan="1">44 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2706 (28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.12</td><td valign="top" align="left" rowspan="1" colspan="1">44 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">145 (25.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Liver disease</td><td valign="top" align="left" rowspan="1" colspan="1">38 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2776 (28.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td><td valign="top" align="left" rowspan="1" colspan="1">38 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">103 (17.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic kidney disease</td><td valign="top" align="left" rowspan="1" colspan="1">19 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2050 (21.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td><td valign="top" align="left" rowspan="1" colspan="1">19 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (8.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Prior alcohol withdrawal</td><td valign="top" align="left" rowspan="1" colspan="1">64 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2999 (31.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td><td valign="top" align="left" rowspan="1" colspan="1">64 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">186 (32.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol-related comorbidity</td><td valign="top" align="left" rowspan="1" colspan="1">20 (10.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1841 (19.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25</td><td valign="top" align="left" rowspan="1" colspan="1">20 (10.4)</td><td valign="top" align="left" rowspan="1" colspan="1">57 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Remote MAUD use</td><td valign="top" align="left" rowspan="1" colspan="1">16 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">171 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30</td><td valign="top" align="left" rowspan="1" colspan="1">16 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Past-year primary care visit</td><td valign="top" align="left" rowspan="1" colspan="1">116 (60.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5201 (53.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.13</td><td valign="top" align="left" rowspan="1" colspan="1">116 (60.4)</td><td valign="top" align="left" rowspan="1" colspan="1">339 (58.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Past-year mental health visit</td><td valign="top" align="left" rowspan="1" colspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1964 (20.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">118 (20.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Past-year hospitalization</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0</td><td valign="top" align="left" rowspan="1" colspan="1">63 (32.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2287 (23.7)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.31</td><td valign="top" align="left" rowspan="1" colspan="1">63 (32.8)</td><td valign="top" align="left" rowspan="1" colspan="1">175 (30.4)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.06</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">43 (22.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1568 (16.3)</td><td valign="top" colspan="1" align="left" rowspan="1">43 (22.4)</td><td valign="top" align="left" rowspan="1" colspan="1">128 (22.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;1</td><td valign="top" align="left" rowspan="1" colspan="1">86 (44.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5787 (60.0)</td><td valign="top" colspan="1" align="left" rowspan="1">86 (44.8)</td><td valign="top" align="left" rowspan="1" colspan="1">273 (47.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Past-year ED visit</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0</td><td valign="top" align="left" rowspan="1" colspan="1">38 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1768 (18.3)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.08</td><td valign="top" align="left" rowspan="1" colspan="1">38 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">109 (18.9)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">36 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1594 (16.5)</td><td valign="top" colspan="1" align="left" rowspan="1">36 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">111 (19.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;1</td><td valign="top" align="left" rowspan="1" colspan="1">118 (61.5)</td><td valign="top" align="left" rowspan="1" colspan="1">6281 (65.1)</td><td valign="top" colspan="1" align="left" rowspan="1">118 (61.5)</td><td valign="top" align="left" rowspan="1" colspan="1">356 (61.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Past-year behavioral therapy</td><td valign="top" align="left" rowspan="1" colspan="1">66 (34.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3091 (32.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td><td valign="top" align="left" rowspan="1" colspan="1">66 (34.4)</td><td valign="top" align="left" rowspan="1" colspan="1">204 (35.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Past 30-d behavioral therapy</td><td valign="top" align="left" rowspan="1" colspan="1">19 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1008 (10.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">19 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (10.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Hospitalization factor</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Discharge diagnosis category</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">106 (55.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4763 (49.4)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.35</td><td valign="top" align="left" rowspan="1" colspan="1">106 (55.2)</td><td valign="top" align="left" rowspan="1" colspan="1">315 (54.7)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mood disorder</td><td valign="top" align="left" rowspan="1" colspan="1">64 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2534 (26.3)</td><td valign="top" colspan="1" align="left" rowspan="1">64 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">201 (34.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other mental health</td><td valign="top" align="left" rowspan="1" colspan="1">22 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2347 (24.3)</td><td valign="top" colspan="1" align="left" rowspan="1">22 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (10.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Elixhauser readmission index, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">17.8 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">21.9 (13.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td><td valign="top" align="left" rowspan="1" colspan="1">17.8 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17.0 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Inpatient addiction medicine or psychiatry</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> None</td><td valign="top" align="left" rowspan="1" colspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3940 (40.9)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.42</td><td valign="top" align="left" rowspan="1" colspan="1">42 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">117 (20.3)</td><td rowspan="3" valign="middle" align="left" colspan="1">0.08</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychiatric hospital</td><td valign="top" align="left" rowspan="1" colspan="1">85 (44.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3225 (33.5)</td><td valign="top" colspan="1" align="left" rowspan="1">85 (44.3)</td><td valign="top" align="left" rowspan="1" colspan="1">278 (48.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychiatry or addiction medicine at general hospital</td><td valign="top" align="left" rowspan="1" colspan="1">65 (33.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2477 (25.7)</td><td valign="top" colspan="1" align="left" rowspan="1">65 (33.9)</td><td valign="top" align="left" rowspan="1" colspan="1">181 (31.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Self-directed discharge</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.30</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Length of stay, mean (SD), d</td><td valign="top" align="left" rowspan="1" colspan="1">8.2 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">6.1 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td><td valign="top" align="left" rowspan="1" colspan="1">8.2 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7.7 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Discharge month</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.35</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MAUD, medications for alcohol use disorder (naltrexone, acamprosate, disulfiram); NR, not reported; SMD, standardized mean difference; ED, emergency department.</p><fn id="zoi240151t1n1"><label>
<sup>a</sup>
</label><p>Self-reported and imputed race and ethnicity were determined using the Research Triangle Institute race code.<sup><xref rid="zoi240151r23" ref-type="bibr">23</xref></sup></p></fn><fn id="zoi240151t1n2"><label>
<sup>b</sup>
</label><p>Other includes Asian, North American Native, and unknown, grouped due to small sample sizes.</p></fn><fn id="zoi240151t1n3"><label>
<sup>c</sup>
</label><p>Redacted due to the Centers for Medicare &amp; Medicaid Services cell suppression policy threshold for display of data (values &lt;11 individuals).</p></fn></table-wrap-foot></table-wrap><sec id="H2-6-ZOI240151"><title>Primary Outcome</title><p>The primary outcome occurred among 4843 hospitalizations (49.3%), including 49 hospitalizations (25.5%) that involved discharge MAUD initiation and 4794 hospitalizations (49.7%) that did not (<xref rid="zoi240151f1" ref-type="fig">Figure 1</xref>A). This was mostly contributed by 3340 all-cause ED visits (34.0%) and 3375 all-cause readmissions (34.3%) within 30 days. There were 97 deaths (1.0%) within 30 days of discharge. After matching, discharge MAUD initiation was associated with a 42% decreased incidence of the primary outcome (IRR, 0.58 [95% CI, 0.45 to 0.76]; ARD, &#8722;0.18 [95% CI, &#8722;0.26 to &#8722;0.11]) (<xref rid="zoi240151t2" ref-type="table">Table 2</xref>).</p><fig position="float" id="zoi240151f1" fig-type="figure" orientation="portrait"><label>Figure 1. </label><caption><title>Unadjusted Posthospitalization Care Patterns After Alcohol-Related Hospitalizations at 30 d</title><p>Return to hospital includes emergency department (ED) visits and hospital readmissions and observation stays. MAUD indicates medications for alcohol use disorder.</p><p><sup>a</sup>Mortality not shown due to the Centers for Medicare &amp; Medicaid Services cell suppression policy threshold for display of data (values &lt;11 individuals).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e243387-g001.jpg"/></fig><table-wrap position="float" id="zoi240151t2" orientation="portrait"><label>Table 2. </label><caption><title>Association Between Discharge Initiation of MAUD and 30-d Composite Primary Outcome</title></caption><table frame="hsides" rules="groups"><col width="18.4%" span="1"/><col width="15.67%" span="1"/><col width="16.52%" span="1"/><col width="16.58%" span="1"/><col width="13.91%" span="1"/><col width="18.92%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Hospitalizations, No. (%) (N&#8201;=&#8201;9834)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Unadjusted IRR (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adjusted IRR (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adjusted ARD (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discharge MAUD initiation (n&#8201;=&#8201;192)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No discharge MAUD initiation (n&#8201;=&#8201;9642)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Primary composite outcome</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Primary composite outcome<xref rid="zoi240151t2n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi240151t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">49 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4794 (49.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.51 (0.40 to 0.65)</td><td valign="top" align="left" rowspan="1" colspan="1">0.58 (0.45 to 0.76)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.18 (&#8722;0.26 to &#8722;0.11)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Individual component</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> All-cause return to hospital<xref rid="zoi240151t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">47 (24.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4770 (49.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.49 (0.39 to 0.64)</td><td valign="top" align="left" rowspan="1" colspan="1">0.56 (0.43 to 0.73)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.19 (&#8722;0.27 to &#8722;0.12)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> All-cause ED visits</td><td valign="top" align="left" rowspan="1" colspan="1">33 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3307 (34.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.50 (0.37 to 0.68)</td><td valign="top" align="left" rowspan="1" colspan="1">0.57 (0.41 to 0.80)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.13 (&#8722;0.20 to &#8722;0.06)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> All-cause readmissions</td><td valign="top" align="left" rowspan="1" colspan="1">22 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3353 (34.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.33 (0.22 to 0.49)</td><td valign="top" align="left" rowspan="1" colspan="1">0.42 (0.27 to 0.63)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.16 (&#8722;0.22 to &#8722;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mortality</td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR<xref rid="zoi240151t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.26 to 4.26)</td><td valign="top" align="left" rowspan="1" colspan="1">3.00 (0.42 to 21.22)</td><td valign="top" align="left" rowspan="1" colspan="1">0.01 (&#8722;0.01 to 0.02)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ARD, absolute risk difference; ED, emergency department; IRR, incident rate ratio; NR, not reported; MAUD, medications for alcohol use disorder.</p><fn id="zoi240151t2n1"><label>
<sup>a</sup>
</label><p>All-cause return to hospital or mortality.</p></fn><fn id="zoi240151t2n2"><label>
<sup>b</sup>
</label><p>Return to hospital includes ED visits and hospital readmissions.</p></fn><fn id="zoi240151t2n3"><label>
<sup>c</sup>
</label><p>Redacted values due to the Centers for Medicare &amp; Medicaid Services cell suppression policy threshold for display of data (values &lt;11 individuals).</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-7-ZOI240151"><title>Secondary Outcomes</title><p>Unadjusted secondary outcomes are shown in <xref rid="zoi240151f1" ref-type="fig">Figure 1</xref>B. In adjusted models, discharge MAUD initiation was associated with a decreased incidence of all-cause ED visits (IRR, 0.57 [95% CI, 0.41 to 0.80]; ARD, &#8722;0.13 [95% CI, &#8722;0.20 to &#8722;0.06]) and all-cause readmissions (IRR, 0.42 [95% CI, 0.27 to 0.63]; ARD, &#8722;0.16 [95% CI, &#8722;0.22 to &#8722;0.10]), but there was no significant difference in mortality (IRR, 3.00 [95% CI, 0.42 to 21.22]; ARD, 0.01 [95% CI, &#8722;0.01 to 0.02]). Discharge MAUD initiation was also associated with decreased incidence of all-cause return to hospital (IRR, 0.56 [95% CI, 0.43 to 0.73]; ARD, &#8722;0.19 [95% CI, &#8722;0.27 to &#8722;0.12]) (<xref rid="zoi240151t2" ref-type="table">Table 2</xref>) and alcohol-related return to hospital (IRR, 0.49 [95% CI, 0.34 to 0.71]; ARD, &#8722;0.15 [95% CI, &#8722;0.22 to &#8722;0.09), which was mostly contributed by alcohol-related readmissions (<xref rid="zoi240151t3" ref-type="table">Table 3</xref>). Alcohol-related ED visits did not reach statistical significance in relative terms (IRR, 0.61 [95% CI, 0.37 to 1.01]; ARD, &#8722;0.05 [95% CI, &#8722;0.11 to &#8722;0.001). Overall, 4290 hospitalizations (43.6%) involved 30-day primary care or mental health follow-up, and discharge MAUD initiation was associated with increased incidence of this outcome (IRR, 1.22 [95% CI, 1.04 to 1.44]; ARD, 0.10 [95% CI, 0.02 to 0.18]).</p><table-wrap position="float" id="zoi240151t3" orientation="portrait"><label>Table 3. </label><caption><title>Association Between Discharge Initiation of MAUD and 30-d Secondary Outcomes</title></caption><table frame="hsides" rules="groups"><col width="19.05%" span="1"/><col width="16.39%" span="1"/><col width="16.53%" span="1"/><col width="17.24%" span="1"/><col width="14.62%" span="1"/><col width="16.17%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Hospitalizations, No. (%) (N&#8201;=&#8201;9834)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Unadjusted IRR (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adjusted IRR (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adjusted ARD (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discharge MAUD initiation (n&#8201;=&#8201;192)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No discharge MAUD initiation (n&#8201;=&#8201;9642)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Alcohol-related return to hospital<xref rid="zoi240151t3n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">28 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3247 (33.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.31 to 0.61)</td><td valign="top" align="left" rowspan="1" colspan="1">0.49 (0.34 to 0.71)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.15 (&#8722;0.22 to &#8722;0.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Alcohol-related ED visits</td><td valign="top" align="left" rowspan="1" colspan="1">17 (8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1635 (17.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.52 (0.33 to 0.83)</td><td valign="top" align="left" rowspan="1" colspan="1">0.61 (0.37 to 1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.05 (&#8722;0.11 to &#8722;0.001)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Alcohol-related readmissions</td><td valign="top" align="left" rowspan="1" colspan="1">15 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2493 (25.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.19 to 0.49)</td><td valign="top" align="left" rowspan="1" colspan="1">0.36 (0.21 to 0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.14 (&#8722;0.19 to &#8722;0.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Primary care or mental health follow-up</td><td valign="top" align="left" rowspan="1" colspan="1">104 (54.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4186 (43.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1.25 (1.09 to 1.42)</td><td valign="top" align="left" rowspan="1" colspan="1">1.22 (1.04 to 1.44)</td><td valign="top" align="left" rowspan="1" colspan="1">0.10 (0.02 to 0.18)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ARD, absolute risk difference; ED, emergency department; IRR, incident rate ratio; MAUD, medications for alcohol use disorder.</p><fn id="zoi240151t3n1"><label>
<sup>a</sup>
</label><p>Return to hospital includes ED visits and hospital readmission.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-8-ZOI240151"><title>Sensitivity Analyses</title><p>Sensitivity analyses yielded consistent point estimates and statistical significance for the association between discharge MAUD initiation and the primary outcome (<xref rid="zoi240151f2" ref-type="fig">Figure 2</xref>). In the analysis restricted to a single hospitalization per patient among 664 patients, the IRR was 0.58 (95% CI, 0.43-0.80), although there were postmatching residual imbalances in discharge month and a greater proportion of patients with more than 1 past-year ED visit in the group that did not receive MAUD (eTable 5 and eFigure 2 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>). In the analysis using propensity overlap weighting among 9834 patients, all covariates were balanced on the mean (eTable 6 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>) and the IRR was 0.61 (95% CI, 0.48, 0.78). In the analysis restricted to 304 patients with a primary AUD discharge diagnosis, there were residual imbalances in discharge month; there was a higher social deprivation index and more frequent anxiety and depression in the group that did not receive MAUD (eTable 7 and eFigure 3 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>), and the IRR was 0.53 (95% CI, 0.36-0.78). In the analysis restricted to 768 patients who had at least 1 medication fill, there were residual imbalances in race and ethnicity and discharge month (eTable 8 and eFigure 4 in <xref rid="note-ZOI240151-1-s" ref-type="supplementary-material">Supplement 1</xref>); the IRR was 0.70 (95% CI, 0.53-0.93). The E-value for the primary analysis was 2.84 for the point estimate and 1.96 for the CI.</p><fig position="float" id="zoi240151f2" fig-type="figure" orientation="portrait"><label>Figure 2. </label><caption><title>Association Between Discharge Initiation and Primary Outcome in Sensitivity Analyses</title><p>Associations are shown between discharge initiation of medications for alcohol use disorder and the primary outcome (composite 30-day all-cause return to hospital or mortality). AUD indicates alcohol use disorder; IRR, incident rate ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e243387-g002.jpg"/></fig></sec></sec><sec id="H1-4-ZOI240151"><title>Discussion</title><p>In this cohort study of a national sample of Medicare Part D beneficiaries with alcohol-related hospitalizations in 2016, discharge MAUD initiation was associated with a 42% relative and 18% absolute reduction in 30-day all-cause mortality or return to hospital. Nearly half of hospitalizations were followed by 30-day mortality or return to hospital, and less than half involved primary care or mental health follow-up. Given the established benefit of providing brief interventions to hospitalized patients with AUD<sup><xref rid="zoi240151r32" ref-type="bibr">32</xref></sup> and the efficacy of MAUD in other care settings,<sup><xref rid="zoi240151r6" ref-type="bibr">6</xref></sup> our findings highlight the potential benefit of interventions to promote behavior change through initiation of MAUD after alcohol-related hospitalizations.</p><p>Our study builds on prior work characterizing clinical outcomes after alcohol-related hospitalizations. We found a higher 30-day readmission rate (34.3%) than a prior study that identified a 14% rate after alcohol-related hospitalizations in 2015.<sup><xref rid="zoi240151r33" ref-type="bibr">33</xref></sup> These differences may be explained by our cohort characteristics, including older age and a high proportion of patients with disabilities. The high rate of return to hospital in the 30 days after alcohol-related hospitalizations and the finding that less than half of such patients attended a primary care or mental health follow-up appointment emphasizes an urgent need to implement interventions to promote more effective transitions of care to the outpatient setting.</p><p>Our study also builds on prior single-center studies of MAUD initiation in hospital settings. Wei et al<sup><xref rid="zoi240151r15" ref-type="bibr">15</xref></sup> performed a preimplementation vs postimplementation study of a discharge-planning tool that increased naltrexone prescribing from 0% to 64% and found an absolute reduction in the rate of 30-day ED visits and readmissions (13% and 15%, respectively). We found a similar absolute risk difference (13% and 16%). Stevens et al<sup><xref rid="zoi240151r16" ref-type="bibr">16</xref></sup> performed a similar preintervention vs postintervention evaluation of an intervention that increased naltrexone prescribing from 2% to 28% for patients admitted with alcohol detoxification or withdrawal through clinician education and dissemination of a decision support tool. This study found a reduction in 30-day ED visits but not readmissions. Although more than 20% of readmissions occur at different hospitals, neither prior study evaluated health care use at other health systems.<sup><xref rid="zoi240151r34" ref-type="bibr">34</xref></sup> An open-label pilot trial<sup><xref rid="zoi240151r35" ref-type="bibr">35</xref></sup> found a 48% relative reduction in 30-day readmissions among patients randomized to injectable naltrexone compared with linkage to care alone. These underpowered results did not reach statistical significance but reflect a similar magnitude of effect size as observed in our study. Our findings add to the existing literature of clinical effectiveness of MAUD in hospital discharge by showing that MAUD initiation was associated with improved posthospitalization outcomes in a national sample.</p><p>One component of interventions to promote AUD treatment engagement in the discharge and posthospitalization setting should include increased MAUD prescribing. Known barriers for prescribing in the inpatient setting include clinician knowledge gaps, concern about discharge follow-up, lack of institutional prioritization, and stigma of AUD.<sup><xref rid="zoi240151r13" ref-type="bibr">13</xref></sup> However, prior implementation efforts around AUD hospitalizations have shown promise.<sup><xref rid="zoi240151r15" ref-type="bibr">15</xref>,<xref rid="zoi240151r16" ref-type="bibr">16</xref></sup> Expansion of existing programs to promote clinician training through video conferencing<sup><xref rid="zoi240151r36" ref-type="bibr">36</xref></sup> and pharmacist-led posthospitalization transition care<sup><xref rid="zoi240151r37" ref-type="bibr">37</xref></sup> may also prove beneficial in expanding treatment access. In addition, interventions should include facilitation of outpatient follow-up, which is needed for monitoring or initiating MAUD (if it did not already occur at discharge), providing counseling, and referring patients to additional behavioral health services.</p><sec id="H2-9-ZOI240151"><title>Limitations</title><p>This study has several limitations. There are inherent limitations of this observational study design, including unmeasured confounding.<sup><xref rid="zoi240151r17" ref-type="bibr">17</xref></sup> The E-value indicates that an unobserved confounder would need to have an IRR of 2.84 to shift our effect size to the null. For example, we were unable to account for healthy user bias or psychosocial factors, including patient motivation. Notably, we observed a large effect size after controlling for multiple observed confounders. The effect size was attenuated in the analysis restricted to patients who had at least 1 discharge medication fill, indicating the presence of some residual confounding, but the effect size remained large and retained statistical significance. Still, our results likely represent upper bound estimates, and a randomized trial is needed to answer this question definitively. Results may not be generalizable to patients who are younger, do not have disabilities, or are Medicare Advantage beneficiaries. Diagnosis codes for case identification of AUD are unable to discern severity of disease, although we were able to use variables for prior withdrawal and alcohol-related health care use as surrogates for severity. Owing to bundled inpatient billing, we were unable to identify rates of long-acting injectable naltrexone that was initiated during hospitalization. However, injectable naltrexone is the least used FDA-approved MAUD,<sup><xref rid="zoi240151r38" ref-type="bibr">38</xref>,<xref rid="zoi240151r39" ref-type="bibr">39</xref></sup> and many hospitals may not have it on formulary.<sup><xref rid="zoi240151r40" ref-type="bibr">40</xref></sup> We were also unable to identify use of nonpharmacologic treatment, including 12-step facilitation or behavioral interventions. Additionally, data from hospitalizations in 2016 may not be representative of current AUD outcomes.</p></sec></sec><sec id="H1-5-ZOI240151"><title>Conclusions</title><p>In this retrospective cohort study of Medicare Part D beneficiaries with alcohol-related hospitalizations, return to hospital within 30 days was common and initiation of MAUD at discharge was associated with a large reduction in return to hospital within 30 days. These findings support ongoing efforts to increase access to MAUD in the posthospitalization setting.</p></sec></body><back><ref-list id="REF-ZOI240151"><title>References</title><ref id="zoi240151r1"><label>1</label><mixed-citation publication-type="webpage">National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. Accessed July 21, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics" ext-link-type="uri">https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics</ext-link></mixed-citation></ref><ref id="zoi240151r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sacks</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Gonzales</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Bouchery</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Tomedi</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Brewer</surname><given-names>RD</given-names></string-name></person-group>. <article-title>2010 National and state costs of excessive alcohol consumption</article-title>. <source>Am J Prev Med</source>. <year>2015</year>;<volume>49</volume>(<issue>5</issue>):<fpage>e73</fpage>-<lpage>e79</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amepre.2015.05.031</pub-id><pub-id pub-id-type="pmid">26477807</pub-id></mixed-citation></ref><ref id="zoi240151r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Reus</surname><given-names>VI</given-names></string-name>, <string-name name-style="western"><surname>Fochtmann</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Bukstein</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder</article-title>. <source>Am J Psychiatry</source>. <year>2018</year>;<volume>175</volume>(<issue>1</issue>):<fpage>86</fpage>-<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2017.1750101</pub-id><pub-id pub-id-type="pmid">29301420</pub-id></mixed-citation></ref><ref id="zoi240151r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Garbutt</surname><given-names>JC</given-names></string-name></person-group>. <article-title>The state of pharmacotherapy for the treatment of alcohol dependence</article-title>. <source>J Subst Abuse Treat</source>. <year>2009</year>;<volume>36</volume>(<issue>1</issue>):<fpage>S15</fpage>-<lpage>S23</lpage>.<pub-id pub-id-type="pmid">19062347</pub-id></mixed-citation></ref><ref id="zoi240151r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM</given-names></string-name></person-group>. <article-title>Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health</article-title>. <source>JAMA Psychiatry</source>. <year>2021</year>;<volume>78</volume>(<issue>8</issue>):<fpage>922</fpage>-<lpage>924</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.1271</pub-id><pub-id pub-id-type="pmid">34132744</pub-id><pub-id pub-id-type="pmcid">PMC8209593</pub-id></mixed-citation></ref><ref id="zoi240151r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jonas</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Amick</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Feltner</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>(<issue>18</issue>):<fpage>1889</fpage>-<lpage>1900</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2014.3628</pub-id><pub-id pub-id-type="pmid">24825644</pub-id></mixed-citation></ref><ref id="zoi240151r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McPheeters</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Riley</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>(<issue>17</issue>):<fpage>1653</fpage>-<lpage>1665</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2023.19761</pub-id><pub-id pub-id-type="pmid">37934220</pub-id><pub-id pub-id-type="pmcid">PMC10630900</pub-id></mixed-citation></ref><ref id="zoi240151r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Heikkinen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taipale</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tanskanen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>L&#228;hteenvuo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></string-name></person-group>. <article-title>Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125&#8201;556 patients</article-title>. <source>Addiction</source>. <year>2021</year>;<volume>116</volume>(<issue>8</issue>):<fpage>1990</fpage>-<lpage>1998</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15384</pub-id><pub-id pub-id-type="pmid">33394527</pub-id><pub-id pub-id-type="pmcid">PMC8359433</pub-id></mixed-citation></ref><ref id="zoi240151r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Singh</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Cleveland</surname><given-names>JD</given-names></string-name></person-group>. <article-title>Trends in hospitalizations for alcohol use disorder in the US From 1998 to 2016</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>9</issue>):<elocation-id>e2016580</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.16580</pub-id><pub-id pub-id-type="pmid">32955569</pub-id></mixed-citation></ref><ref id="zoi240151r10"><label>10</label><mixed-citation publication-type="webpage"><person-group><collab>Joint Commission</collab></person-group>. Specifications Manual for Joint Commission national quality measures (v2023A). Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://manual.jointcommission.org/releases/TJC2023A/MIF0221.html" ext-link-type="uri">https://manual.jointcommission.org/releases/TJC2023A/MIF0221.html</ext-link></mixed-citation></ref><ref id="zoi240151r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bernstein</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Baggett</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Herzig</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>TS</given-names></string-name></person-group>. <article-title>Pharmacologic treatment initiation among Medicare Beneficiaries hospitalized with alcohol use disorder</article-title>. <source>Ann Intern Med</source>. <year>2023</year>;<volume>176</volume>(<issue>8</issue>):<fpage>1137</fpage>-<lpage>1139</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M23-0641</pub-id><pub-id pub-id-type="pmid">37364264</pub-id><pub-id pub-id-type="pmcid">PMC10910351</pub-id></mixed-citation></ref><ref id="zoi240151r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bernstein</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Pfoh</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rothberg</surname><given-names>MB</given-names></string-name></person-group>. <article-title>Relationship between primary care providers&#8217; perceptions of alcohol use disorder and pharmacotherapy prescribing rates</article-title>. <source>Alcohol Alcohol</source>. <year>2023</year>;<volume>58</volume>(<issue>1</issue>):<fpage>54</fpage>-<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1093/alcalc/agac057</pub-id><pub-id pub-id-type="pmid">36368012</pub-id></mixed-citation></ref><ref id="zoi240151r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Joudrey</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Oldfield</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Yonkers</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Berland</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></string-name></person-group>. <article-title>Inpatient adoption of medications for alcohol use disorder: a mixed-methods formative evaluation involving key stakeholders</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>213</volume>:<elocation-id>108090</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108090</pub-id><pub-id pub-id-type="pmid">32559667</pub-id><pub-id pub-id-type="pmcid">PMC7375447</pub-id></mixed-citation></ref><ref id="zoi240151r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kirchoff</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Mohammed</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Naltrexone initiation in the inpatient setting for alcohol use disorder: a systematic review of clinical outcomes</article-title>. <source>Mayo Clin Proc Innov Qual Outcomes</source>. <year>2021</year>;<volume>5</volume>(<issue>2</issue>):<fpage>495</fpage>-<lpage>501</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mayocpiqo.2021.01.013</pub-id><pub-id pub-id-type="pmid">33997645</pub-id><pub-id pub-id-type="pmcid">PMC8105524</pub-id></mixed-citation></ref><ref id="zoi240151r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Defries</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lozada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Tulsky</surname><given-names>J</given-names></string-name></person-group>. <article-title>An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits</article-title>. <source>J Gen Intern Med</source>. <year>2015</year>;<volume>30</volume>(<issue>3</issue>):<fpage>365</fpage>-<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-014-2968-9</pub-id><pub-id pub-id-type="pmid">25092008</pub-id><pub-id pub-id-type="pmcid">PMC4351284</pub-id></mixed-citation></ref><ref id="zoi240151r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stephens</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stepanek</surname><given-names>KV</given-names></string-name>, <etal/></person-group>. <article-title>Implementation of a process for initiating naltrexone in patients hospitalized for alcohol detoxification or withdrawal</article-title>. <source>J Hosp Med</source>. <year>2018</year>;<volume>13</volume>(<issue>4</issue>):<fpage>221</fpage>-<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.12788/jhm.2900</pub-id><pub-id pub-id-type="pmid">29364992</pub-id></mixed-citation></ref><ref id="zoi240151r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Leaf</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Target trial emulation: a framework for causal inference from observational data</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>328</volume>(<issue>24</issue>):<fpage>2446</fpage>-<lpage>2447</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.21383</pub-id><pub-id pub-id-type="pmid">36508210</pub-id></mixed-citation></ref><ref id="zoi240151r18"><label>18</label><mixed-citation publication-type="webpage"><person-group><collab>Healthcare Cost and Utilization Project</collab></person-group>. Clinical classifications software (CCS) for <italic toggle="yes">ICD-10-PCS</italic>. (beta version). Accessed July 21, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp" ext-link-type="uri">https://hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp</ext-link></mixed-citation></ref><ref id="zoi240151r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Stano</surname><given-names>CM</given-names></string-name>, <etal/></person-group>. <article-title>Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use</article-title>. <source>BMC Health Serv Res</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>18</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1472-6963-12-18</pub-id><pub-id pub-id-type="pmid">22270080</pub-id><pub-id pub-id-type="pmcid">PMC3280157</pub-id></mixed-citation></ref><ref id="zoi240151r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Moore</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Washington</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Coenen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Elixhauser</surname><given-names>A</given-names></string-name></person-group>. <article-title>Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index</article-title>. <source>Med Care</source>. <year>2017</year>;<volume>55</volume>(<issue>7</issue>):<fpage>698</fpage>-<lpage>705</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MLR.0000000000000735</pub-id><pub-id pub-id-type="pmid">28498196</pub-id></mixed-citation></ref><ref id="zoi240151r21"><label>21</label><mixed-citation publication-type="webpage"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. <source>Alcohol and public health: alcohol-related disease impact (ARDI): annual average for United States 2015-2019: alcohol-attributable deaths due to excessive alcohol use</source>. Accessed July 21, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&amp;P=612EF325-9B55-442B-AE0C-789B06E3A8D5&amp;R=C877B524-834A-47D5-964D-158FE519C894&amp;M=DB4DAAC0-C9B3-4F92-91A5-A5781DA85B68&amp;F=&amp;D=" ext-link-type="uri">https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&amp;P=612EF325-9B55-442B-AE0C-789B06E3A8D5&amp;R=C877B524-834A-47D5-964D-158FE519C894&amp;M=DB4DAAC0-C9B3-4F92-91A5-A5781DA85B68&amp;F=&amp;D=</ext-link></mixed-citation></ref><ref id="zoi240151r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>L&#233;vesque</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Hanley</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kezouh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suissa</surname><given-names>S</given-names></string-name></person-group>. <article-title>Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<fpage>b5087</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.b5087</pub-id><pub-id pub-id-type="pmid">20228141</pub-id></mixed-citation></ref><ref id="zoi240151r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Eicheldinger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bonito</surname><given-names>A</given-names></string-name></person-group>. <article-title>More accurate racial and ethnic codes for Medicare administrative data</article-title>. <source>Health Care Financ Rev</source>. <year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>27</fpage>-<lpage>42</lpage>.<pub-id pub-id-type="pmid">18567241</pub-id><pub-id pub-id-type="pmcid">PMC4195038</pub-id></mixed-citation></ref><ref id="zoi240151r24"><label>24</label><mixed-citation publication-type="webpage"><person-group><collab>Robert Graham Center</collab></person-group>. Social deprivation index (SDI). Accessed November 16, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.graham-center.org/rgc/maps-data-tools/social-deprivation-index.html" ext-link-type="uri">https://www.graham-center.org/rgc/maps-data-tools/social-deprivation-index.html</ext-link></mixed-citation></ref><ref id="zoi240151r25"><label>25</label><mixed-citation publication-type="webpage"><person-group><collab>Chronic Conditions Data Warehouse</collab></person-group>. Chronic conditions. Accessed December 28, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.ccwdata.org/web/guest/condition-categories-chronic" ext-link-type="uri">https://www2.ccwdata.org/web/guest/condition-categories-chronic</ext-link></mixed-citation></ref><ref id="zoi240151r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nowels</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name></person-group>. <article-title>Buprenorphine after nonfatal opioid overdose: reduced mortality risk in Medicare disability beneficiaries</article-title>. <source>Am J Prev Med</source>. <year>2023</year>;<volume>65</volume>(<issue>1</issue>):<fpage>19</fpage>-<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amepre.2023.01.037</pub-id><pub-id pub-id-type="pmid">36906496</pub-id><pub-id pub-id-type="pmcid">PMC10293066</pub-id></mixed-citation></ref><ref id="zoi240151r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Austin</surname><given-names>PC</given-names></string-name></person-group>. <article-title>Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples</article-title>. <source>Stat Med</source>. <year>2009</year>;<volume>28</volume>(<issue>25</issue>):<fpage>3083</fpage>-<lpage>3107</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.3697</pub-id><pub-id pub-id-type="pmid">19757444</pub-id><pub-id pub-id-type="pmcid">PMC3472075</pub-id></mixed-citation></ref><ref id="zoi240151r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Austin</surname><given-names>PC</given-names></string-name></person-group>. <article-title>An introduction to propensity score methods for reducing the effects of confounding in observational studies</article-title>. <source>Multivariate Behav Res</source>. <year>2011</year>;<volume>46</volume>(<issue>3</issue>):<fpage>399</fpage>-<lpage>424</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00273171.2011.568786</pub-id><pub-id pub-id-type="pmid">21818162</pub-id><pub-id pub-id-type="pmcid">PMC3144483</pub-id></mixed-citation></ref><ref id="zoi240151r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Holmberg</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>LW</given-names></string-name></person-group>. <article-title>Estimating risk ratios and risk differences: alternatives to odds ratios</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>11</issue>):<fpage>1098</fpage>-<lpage>1099</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.12698</pub-id><pub-id pub-id-type="pmid">32930746</pub-id></mixed-citation></ref><ref id="zoi240151r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Thomas</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>23</issue>):<fpage>2417</fpage>-<lpage>2418</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.7819</pub-id><pub-id pub-id-type="pmid">32369102</pub-id></mixed-citation></ref><ref id="zoi240151r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>VanderWeele</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>P</given-names></string-name></person-group>. <article-title>Sensitivity analysis in observational research: introducing the E-value</article-title>. <source>Ann Intern Med</source>. <year>2017</year>;<volume>167</volume>(<issue>4</issue>):<fpage>268</fpage>-<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M16-2607</pub-id><pub-id pub-id-type="pmid">28693043</pub-id></mixed-citation></ref><ref id="zoi240151r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McQueen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Howe</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Allan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mains</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>V</given-names></string-name></person-group>. <article-title>Brief interventions for heavy alcohol users admitted to general hospital wards</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2011</year>;<volume>2011</volume>(<issue>8</issue>):<elocation-id>CD005191</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD005191.pub3</pub-id><pub-id pub-id-type="pmid">21833953</pub-id><pub-id pub-id-type="pmcid">PMC10600352</pub-id></mixed-citation></ref><ref id="zoi240151r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Silverstein</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Kee</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gleeson</surname><given-names>CD</given-names></string-name>, <etal/></person-group>. <article-title>Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015</article-title>. <source>Alcohol</source>. <year>2020</year>;<volume>89</volume>:<fpage>19</fpage>-<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.alcohol.2020.08.003</pub-id><pub-id pub-id-type="pmid">32777472</pub-id></mixed-citation></ref><ref id="zoi240151r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Paik</surname><given-names>MC</given-names></string-name>, <etal/></person-group>. <article-title>Predictors and outcomes of unplanned readmission to a different hospital</article-title>. <source>Int J Qual Health Care</source>. <year>2015</year>;<volume>27</volume>(<issue>6</issue>):<fpage>513</fpage>-<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1093/intqhc/mzv082</pub-id><pub-id pub-id-type="pmid">26472739</pub-id><pub-id pub-id-type="pmcid">PMC4665363</pub-id></mixed-citation></ref><ref id="zoi240151r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Terasaki</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Loh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cornell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taub</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thurstone</surname><given-names>C</given-names></string-name></person-group>. <article-title>Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates</article-title>. <source>Addict Sci Clin Pract</source>. <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>64</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13722-022-00345-y</pub-id><pub-id pub-id-type="pmid">36419181</pub-id><pub-id pub-id-type="pmcid">PMC9682826</pub-id></mixed-citation></ref><ref id="zoi240151r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Komaromy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Duhigg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Metcalf</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders</article-title>. <source>Subst Abus</source>. <year>2016</year>;<volume>37</volume>(<issue>1</issue>):<fpage>20</fpage>-<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2015.1129388</pub-id><pub-id pub-id-type="pmid">26848803</pub-id><pub-id pub-id-type="pmcid">PMC4873719</pub-id></mixed-citation></ref><ref id="zoi240151r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Smith</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Colvard</surname><given-names>M</given-names></string-name></person-group>. <article-title>Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>130</volume>:<elocation-id>108440</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108440</pub-id><pub-id pub-id-type="pmid">34118708</pub-id></mixed-citation></ref><ref id="zoi240151r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bernstein</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rothberg</surname><given-names>MB</given-names></string-name></person-group>. <article-title>Characterizing the variation of alcohol cessation pharmacotherapy in primary care</article-title>. <source>J Gen Intern Med</source>. <year>2021</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1989</fpage>-<lpage>1996</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-020-06454-1</pub-id><pub-id pub-id-type="pmid">33515195</pub-id><pub-id pub-id-type="pmcid">PMC8298666</pub-id></mixed-citation></ref><ref id="zoi240151r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chockalingam</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Burnham</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Jolley</surname><given-names>SE</given-names></string-name></person-group>. <article-title>Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2022</year>;<volume>46</volume>(<issue>6</issue>):<fpage>1094</fpage>-<lpage>1102</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acer.14837</pub-id><pub-id pub-id-type="pmid">35723682</pub-id><pub-id pub-id-type="pmcid">PMC9246874</pub-id></mixed-citation></ref><ref id="zoi240151r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Danovitch</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nuckols</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname><given-names>KE</given-names></string-name>, <etal/></person-group>. <article-title>Alcohol use disorder among general hospital medical inpatients</article-title>. <source>Addiction Research</source>. <year>2021</year>;<volume>5</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.33425/2639-8451.1024</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI240151-1"><supplementary-material id="note-ZOI240151-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> Components of a Theoretical Target Trial and Emulation</p><p><bold>eTable 2.</bold> Identification of Alcohol-Related Disease</p><p><bold>eTable 3.</bold> Identification of Primary Care or Mental Health Follow-Up</p><p><bold>eTable 4.</bold> Identification of Addiction Medicine or Psychiatry Involvement During Hospitalization</p><p><bold>eTable 5.</bold> Characteristics Before and After Propensity Matching in Sensitivity Analysis Restricted to Single Hospitalization per Patient</p><p><bold>eTable 6.</bold> Characteristics Before and After Weighting in Sensitivity Analysis Using Overlap Propensity Weighting</p><p><bold>eTable 7.</bold> Characteristics Before and After Propensity Matching in Sensitivity Analysis Restricted to Primary Alcohol Use Disorder Discharge Diagnosis</p><p><bold>eTable 8.</bold> Characteristics Before and After Propensity Matching in Sensitivity Analysis Restricted to Patients With &gt;1 Discharge Medication Fill</p><p><bold>eFigure 1.</bold> Propensity Score Distribution Before and After 3:1 Matching in Primary Analysis</p><p><bold>eFigure 2.</bold> Propensity Score Distribution Before and After 3:1 Matching in Sensitivity Analysis Restricted to a Single Hospitalization per Patient</p><p><bold>eFigure 3.</bold> Propensity Score Distribution Before and After 3:1 Matching in Sensitivity Analysis Restricted to Primary Alcohol Use Disorder Discharge Diagnoses</p><p><bold>eFigure 4.</bold> Propensity Score Distribution Before and After 3:1 Matching in Sensitivity Analysis Restricted to Patients With &gt;1 Discharge Medication Fill</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e243387-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e243387-s002.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article></pmc-articleset>